c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

被引:244
作者
Blasco, Rafael B.
Francoz, Sarah
Santamaria, David
Canamero, Marta [1 ]
Dubus, Pierre [2 ]
Charron, Jean [3 ]
Baccarini, Manuela [4 ]
Barbacid, Mariano [1 ]
机构
[1] CNIO, Biotechnol Programmes, E-28029 Madrid, Spain
[2] Univ Bordeaux, EA2406, F-33076 Bordeaux, France
[3] Univ Laval, CRCHUQ, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada
[4] Univ Vienna, Ctr Mol Biol, Max F Perutz Labs, A-1030 Vienna, Austria
基金
欧洲研究理事会; 加拿大健康研究院;
关键词
ORAL MEK INHIBITOR; PHASE-II; TUMOR PROGRESSION; MAP KINASE; CANCER; BRAF; ERK; REVEALS; PATHWAY; GROWTH;
D O I
10.1016/j.ccr.2011.04.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have investigated the role of individual members of the Raf/Mek/Erk cascade in the onset of K-Ras oncogene-driven non-small cell lung carcinoma (NSCLC). Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing lung cells had no significant effect due to compensatory activities. Yet, elimination of both Erk kinases completely blocked tumor development. Similar results were obtained with Mek kinases. Ablation of B-Raf had no significant effect on tumor development. However, c-Raf expression was absolutely essential for the onset of NSCLC. Interestingly, concomitant elimination of c-Raf and B-Raf in adult mice had no deleterious consequences for normal homeostasis. These results indicate that c-Raf plays a unique role in mediating K-Ras signaling and makes it a suitable target for therapeutic intervention.
引用
收藏
页码:652 / 663
页数:12
相关论文
共 50 条
  • [41] Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
    Rinehart, J
    Adjei, AA
    LoRusso, PM
    Waterhouse, D
    Hecht, JR
    Natale, RB
    Hamid, O
    Varterasian, M
    Asbury, P
    Kaldjian, EP
    Gulyas, S
    Mitchell, DY
    Herrera, R
    Sebolt-Leopold, JS
    Meyer, MB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4456 - 4462
  • [42] Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia
    Scholl, Florence A.
    Dumesic, Phillip A.
    Barragan, Deborah I.
    Harada, Kazutoshi
    Charron, Jean
    Khavari, Paul A.
    [J]. CANCER RESEARCH, 2009, 69 (09) : 3772 - 3778
  • [43] Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection
    Simpson, AJ
    Wallace, WAH
    Marsden, ME
    Govan, JRW
    Porteous, DJ
    Haslett, C
    Sallenave, JM
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (03) : 1778 - 1786
  • [44] A Gene Expression Signature Associated with "K-Ras Addiction" Reveals Regulators of EMT and Tumor Cell Survival
    Singh, Anurag
    Greninger, Patricia
    Rhodes, Daniel
    Koopman, Louise
    Violette, Sheila
    Bardeesy, Nabeel
    Settleman, Jeff
    [J]. CANCER CELL, 2009, 15 (06) : 489 - 500
  • [45] Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells
    Takezawa, Ken
    Okamoto, Isamu
    Yonesaka, Kimio
    Hatashita, Erina
    Yamada, Yuki
    Fukuoka, Masahiro
    Nakagawa, Kazuhiko
    [J]. CANCER RESEARCH, 2009, 69 (16) : 6515 - 6521
  • [46] Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    Tsai, James
    Lee, John T.
    Wang, Weiru
    Zhang, Jiazhong
    Cho, Hanna
    Mamo, Shumeye
    Bremer, Ryan
    Gillette, Sam
    Kong, Jun
    Haass, Nikolas K.
    Sproesser, Katrin
    Li, Ling
    Smalley, Keiran S. M.
    Fong, Daniel
    Zhu, Yong-Liang
    Marimuthu, Adhirai
    Nguyen, Hoa
    Lam, Billy
    Liu, Jennifer
    Cheung, Ivana
    Rice, Julie
    Suzuki, Yoshihisa
    Luu, Catherine
    Settachatgul, Calvin
    Shellooe, Rafe
    Cantwell, John
    Kim, Sung-Hou
    Schlessinger, Joseph
    Zhang, Kam Y. J.
    West, Brian L.
    Powell, Ben
    Habets, Gaston
    Zhang, Chao
    Ibrahim, Prabha N.
    Hirth, Peter
    Artis, Dean R.
    Herlyn, Meenhard
    Bollag, Gideon
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (08) : 3041 - 3046
  • [47] Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects
    Tuveson, DA
    Shaw, AT
    Willis, NA
    Silver, DP
    Jackson, EL
    Chang, S
    Mercer, KL
    Grochow, R
    Hock, H
    Crowley, D
    Hingorani, SR
    Zaks, T
    King, C
    Jacobetz, MA
    Wang, LF
    Bronson, RT
    Orkin, SH
    DePinho, RA
    Jacks, T
    [J]. CANCER CELL, 2004, 5 (04) : 375 - 387
  • [48] Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
    Villanueva, Jessie
    Vultur, Adina
    Lee, John T.
    Somasundaram, Rajasekharan
    Fukunaga-Kalabis, Mizuho
    Cipolla, Angela K.
    Wubbenhorst, Bradley
    Xu, Xiaowei
    Gimotty, Phyllis A.
    Kee, Damien
    Santiago-Walker, Ademi E.
    Letrero, Richard
    D'Andrea, Kurt
    Pushparajan, Anitha
    Hayden, James E.
    Brown, Kimberly Dahlman
    Laquerre, Sylvie
    McArthur, Grant A.
    Sosman, Jeffrey A.
    Nathanson, Katherine L.
    Herlyn, Meenhard
    [J]. CANCER CELL, 2010, 18 (06) : 683 - 695
  • [49] Four human Ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility
    Voice, JK
    Klemke, RL
    Le, A
    Jackson, JH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) : 17164 - 17170
  • [50] Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis
    Yamaguchi, O
    Watanabe, T
    Nishida, K
    Kashiwase, K
    Higuchi, Y
    Takeda, T
    Hikoso, S
    Hirotani, S
    Asahi, M
    Taniike, M
    Nakai, A
    Tsujimoto, I
    Matsumura, Y
    Miyazaki, J
    Chien, KR
    Matsuzawa, A
    Sadamitsu, C
    Ichijo, H
    Baccarini, M
    Hori, M
    Otsu, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (07) : 937 - 943